Lisinopril 5mg tablets

Land: Verenigd Koninkrijk

Taal: Engels

Bron: MHRA (Medicines & Healthcare Products Regulatory Agency)

Werkstoffen:

Lisinopril

Beschikbaar vanaf:

Arrow Generics Ltd

ATC-code:

C09AA03

INN (Algemene Internationale Benaming):

Lisinopril

Dosering:

5mg

farmaceutische vorm:

Oral tablet

Toedieningsweg:

Oral

klasse:

No Controlled Drug Status

Prescription-type:

Valid as a prescribable product

Product samenvatting:

BNF: 02050501; GTIN: 5060034831983

Bijsluiter

296x210 Leaflet Reel Fed Bi Fold Profile (BST)
Dimensions:
Component:
Date Sent:
Technologist: TECHNICALLY APPROVED
Pharmacode:
JDE No.:
Lisinopril, Capsules, 2.5, 5, 10,
20mg, 28s & UK
296x210 (Reel Fed)
50979114
Leaflet for Blisters
3433
RH
23-09-19
* Please note that ONLY Artwork Studio is permitted to make changes to
the above artwork.
No changes are permitted by any 3rd party other than added notes and
mark ups for required changes.
approved for print/date
PROOF ROUND
[e-mail]
Technical
Approval
NON PRINTING COLOURS
COLOURS
DATE SENT:
DATE RECEIVED:
Item number:
ORIGINATOR:
ORIGINATION DATE:
REVISION DATE:
REVISED BY:
DIMENSIONS:
MIN BODY TEXT SIZE:
SUPPLIER:
1.
2.
3.
4.
5.
6.
1.
2.
3.
FMD info
NA (not a carton)

No

Yes

Details
LISINOPRIL 2.5MG, 5MG, 10MG & 20MG 28 TABLETS PIL - UK
Black
Profile
BBBA6371
RH
25-09-19
10-10-19
RH
296 x 210
7pt
Accord Barnstaple
n/a
n/a
03
Version 2
01.11.2017
page 4
page 1
50979114 BBBA6371
LISINOPRIL 2.5MG, 5MG, 10MG
AND 20MG TABLETS
_Continued over page_
_Continued top of next column_
READ ALL OF THIS LEAFLET CAREFULLY BEFORE
YOU START TAKING THIS MEDICINE BECAUSE IT
CONTAINS IMPORTANT INFORMATION FOR YOU.
• Keep this leaflet. You may need to read
it again.
• If you have any further questions, ask
your doctor or pharmacist.
• This medicine has been prescribed for
you only. Do not pass it on to others. It
may harm them, even if their signs of
illness are the same as yours.
• If you get any side effects, talk to your
doctor or pharmacist. This includes any
possible side effects not listed in this
leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1
WHAT LISINOPRIL TABLETS ARE AND
WHAT THEY ARE USED FOR
2
WHAT YOU NEED TO KNOW BEFORE YOU
TAKE LISINOPRIL TABLETS
3
HOW TO TAKE LISINOPRIL TABLETS
4
POSSIBLE SIDE EFFECTS
5
HOW TO STORE LISINOPRIL TABLETS
6
CONTENTS OF THE PACK AND OTHER
INFORMATION
1
WHAT LISINOPRIL TABLETS ARE AND
WHAT THEY ARE USED FOR
Lisinopril belongs to a group of medicines called
ACE inhibitors. These cau

Productkenmerken

OBJECT 1
LISINOPRIL 5MG TABLETS
Summary of Product Characteristics Updated 13-Nov-2019 | Accord-UK Ltd
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
LISINOPRIL 5mg TABLETS
2. Qualitative and quantitative composition
Each tablet contains 5mg of Lisinopril as Lisinopril dihydrate.
For the full list excipients, see section 6.1.
3. Pharmaceutical form
Tablet
White, round, flat 8 mm tablets, scored on both sides.
The tablet can be divided into equal halves.
4. Clinical particulars
4.1 Therapeutic indications
• Hypertension: Treatment of hypertension.
• Heart failure: Treatment of symptomatic heart failure.
• Acute myocardial infarction: Short-term (6 weeks) treatment of
haemodynamically stable patients within 24
hours of an acute myocardial infarction.
• Renal complications of diabetes mellitus: Treatment of renal
disease in hypertensive patients with Type 2
diabetes mellitus and incipient nephropathy (see section 5.1).
4.2 Posology and method of administration
POSO